The North America Non Hodgkin Lymphoma Therapeutics Market would witness market growth of 7.8% CAGR during the forecast period (2023-2030).
Traditional chemotherapeutic agents, such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), are commonly used to induce remission in NHL. These agents target rapidly dividing cells and aim to eliminate cancerous lymphocytes. Agents like rituximab, a monoclonal antibody targeting the CD20 antigen on B-cells, have been widely combined with chemotherapy to enhance treatment responses and improve remission rates. Emerging targeted therapies, such as BTK inhibitors (e.g., ibrutinib) and PI3K inhibitors (e.g., idelalisib), are increasingly employed in first line and relapsed/refractory settings to induce remission and extend progression-free survival.
Monoclonal antibodies, including rituximab, can be utilized as maintenance therapy following induction to prolong remission. This approach is particularly relevant in certain subtypes of NHL, contributing to sustained disease control. Novel agents like BTK inhibitors may be used in a maintenance capacity to prevent disease relapse, especially in patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Chimeric Antigen Receptor T-cell (CAR-T) therapies, such as axicabtagene ciloleucel and tisagenlecleucel, have shown remarkable efficacy in treating relapsed or refractory NHL. These therapies involve engineering a patient's T-cells to recognize and eliminate cancer cells.
National and regional cancer registries in Mexico collect and analyze data on cancer cases, including NHL. Improved access to healthcare services, diagnostic tools, and medical expertise can lead to better detection and reporting of cancer cases, contributing to the perception of cancer growth in Mexico. Increased awareness of cancer symptoms and the implementation of cancer screening programs can lead to earlier detection and diagnosis of NHL cases in Mexico. As per the National Library of Medicine, NHL is the ninth leading cause of cancer in Mexico, accounting for 3.1% of all cancers. Hence, the factors mentioned above will drive the regional market growth.
The US market dominated the North America Non Hodgkin Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4,768.5 Million by 2030. The Canada market is registering a CAGR of 10.2% during (2023 - 2030). Additionally, The Mexico market would showcase a CAGR of 9.3% during (2023 - 2030).
Free Valuable Insights: The Non Hodgkin Lymphoma Therapeutics Market is Predict to reach $16.8 Billion by 2030, at a CAGR of 8.4%
Based on Cell Type, the market is segmented into B-Cell Lymphoma and T-Cell Lymphoma. Based on Therapy Type, the market is segmented into Radiation Therapy, Chemotherapy, Targeted Therapy, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Pfizer Inc.
- F.Hoffmann-La Roche Ltd
- Sanofi S.A.
- AbbVie, Inc.
- Novartis AG
- GlaxoSmithKline PLC
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Bristol-Myers Squibb Company
North America Non Hodgkin Lymphoma Therapeutics Market Report Segmentation
By Cell Type
- B-Cell Lymphoma
- T-Cell Lymphoma
By Therapy Type
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Non Hodgkin Lymphoma Therapeutics Market, by Cell Type
1.4.2 North America Non Hodgkin Lymphoma Therapeutics Market, by Therapy Type
1.4.3 North America Non Hodgkin Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Non Hodgkin Lymphoma Therapeutics Market.
Chapter 5. North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type
5.1 North America B-Cell Lymphoma Market by Country
5.2 North America T-Cell Lymphoma Market by Country
Chapter 6. North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
6.1 North America Radiation Therapy Market by Country
6.2 North America Chemotherapy Market by Country
6.3 North America Targeted Therapy Market by Country
6.4 North America Others Market by Country
Chapter 7. North America Non Hodgkin Lymphoma Therapeutics Market by Country
7.1 US Non Hodgkin Lymphoma Therapeutics Market
7.1.1 US Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.2 US Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2 Canada Non Hodgkin Lymphoma Therapeutics Market
7.2.1 Canada Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.2 Canada Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3 Mexico Non Hodgkin Lymphoma Therapeutics Market
7.3.1 Mexico Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.2 Mexico Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4 Rest of North America Non Hodgkin Lymphoma Therapeutics Market
7.4.1 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.2 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
Chapter 8. Company Profiles
8.1 Pfizer, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional & Segmental Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.1.5.3 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.6 SWOT Analysis
8.4 AbbVie, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 GlaxoSmithKline PLC
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson (Johnson & Johnson Services, Inc.)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental &Regional Analysis
8.7.4 SWOT Analysis
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Bayer AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. Bristol-Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis
TABLE 1 North America Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 North America Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 3 North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 4 North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 5 North America B-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 6 North America B-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 7 North America T-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 8 North America T-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 9 North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 10 North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 11 North America Radiation Therapy Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Radiation Therapy Market by Country, 2023 - 2030, USD Million
TABLE 13 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 17 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 19 North America Non Hodgkin Lymphoma Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Non Hodgkin Lymphoma Therapeutics Market by Country, 2023 - 2030, USD Million
TABLE 21 US Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 22 US Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 23 US Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 24 US Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 25 US Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 26 US Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 27 Canada Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 28 Canada Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 29 Canada Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 30 Canada Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 31 Canada Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 32 Canada Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 33 Mexico Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 34 Mexico Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 35 Mexico Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 36 Mexico Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 37 Mexico Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 38 Mexico Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 39 Rest of North America Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 40 Rest of North America Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 41 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 42 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 43 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 44 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 45 Key Information – Pfizer, Inc.
TABLE 46 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 47 Key Information – Sanofi S.A.
TABLE 48 Key information – AbbVie, Inc.
TABLE 49 Key Information – Novartis AG
TABLE 50 Key Information – GlaxoSmithKline PLC
TABLE 51 Key Information – Johnson & Johnson
TABLE 52 Key Information – Takeda Pharmaceutical Company Limited
TABLE 53 Key Information – Bayer AG
TABLE 54 Key Information – Bristol-Myers Squibb Company
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Non Hodgkin Lymphoma Therapeutics Market
FIG 4 Porter’s Five Forces Analysis – Non Hodgkin Lymphoma Therapeutics Market
FIG 5 North America Non Hodgkin Lymphoma Therapeutics Market share by Cell Type, 2022
FIG 6 North America Non Hodgkin Lymphoma Therapeutics Market share by Cell Type, 2030
FIG 7 North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2030, USD Million
FIG 8 North America Non Hodgkin Lymphoma Therapeutics Market share by Therapy Type, 2022
FIG 9 North America Non Hodgkin Lymphoma Therapeutics Market share by Therapy Type, 2030
FIG 10 North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2030, USD Million
FIG 11 North America Non Hodgkin Lymphoma Therapeutics Market share by Country, 2022
FIG 12 North America Non Hodgkin Lymphoma Therapeutics Market share by Country, 2030
FIG 13 North America Non Hodgkin Lymphoma Therapeutics Market by Country, 2019 - 2030, USD Million
FIG 14 Recent strategies and developments: Pfizer Inc.
FIG 15 SWOT Analysis: Pfizer, Inc.
FIG 16 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 17 Swot Analysis: Sanofi S.A.
FIG 18 Swot Analysis: AbbVie, Inc.
FIG 19 SWOT Analysis: Novartis AG
FIG 20 SWOT Analysis: GlaxoSmithKline PLC
FIG 21 SWOT Analysis: Johnson & Johnson
FIG 22 SWOT Analysis:Takeda Pharmaceutical Company Limited
FIG 23 Swot Analysis: Bayer AG
FIG 24 SWOT Analysis: Bristol-Myers Squibb Company